05th week of 2015 patent applcation highlights part 49 |
Patent application number | Title | Published |
20150031672 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. | 2015-01-29 |
20150031673 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 2015-01-29 |
20150031674 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein R | 2015-01-29 |
20150031675 | DIAZABICYCLO[3.3.1]NONANES, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). | 2015-01-29 |
20150031676 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF - This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases. | 2015-01-29 |
20150031677 | TRIOXANE THIOACETAL MONOMERS AND DIMERS AND METHODS OF USE THEREOF - Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer. | 2015-01-29 |
20150031678 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to new substituted pyrazolo[1,5-a]pyridine having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments. | 2015-01-29 |
20150031679 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK - Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus. | 2015-01-29 |
20150031680 | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof - The present invention relates to the long-term administration of a selective estrogen receptor modulator (SERM) with a short half-life for the treatment of a variety of estrogen receptor-mediated conditions. The SERM may be administered at a concentration at or below that of a SERM with a long half-life in order to achieve an equivalent therapeutic effect. | 2015-01-29 |
20150031681 | NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE - A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I): | 2015-01-29 |
20150031682 | ANTI-MALARIAL AGENTS - The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation. | 2015-01-29 |
20150031683 | RHO KINASE INHIBITORS FOR USE IN TREATING AMYOTROPHIC LATERAL SCLEROSIS - The invention relates to a new use of a known Rho kinase inhibitor, fasudil or a fasudil derivative selected from hydroy-fasudil or dimethylfasudil, in the treatment of amyotrophic lateral sclerosis (ALS). | 2015-01-29 |
20150031684 | SWEET FLAVOR MODIFIER - The present invention includes compounds having structural formula (I), or salts or solvates thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of modulating the sweet taste of compositions. | 2015-01-29 |
20150031686 | PHENYL-OXAZOLYL DERIVATIVES, PREPARATION METHOD THEREOF, AND RELATED APPLICATION OF THE PHENYL-OXAZOLYL DERIVATIVES AS AN IMPDH INHIBITOR - Disclosed are phenyl-oxazolyl derivatives having a general formula (I), a preparation method thereof, and an application of the phenyl-oxazolyl derivatives as an inosine monophosphate dehydrogenase (IMPDH) inhibitor. | 2015-01-29 |
20150031687 | Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection - The invention provides novel compounds having the general formula: | 2015-01-29 |
20150031688 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS - A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and αvβ3 integrin antagonist in the same molecule. | 2015-01-29 |
20150031689 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES - The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: Such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, such as obesity, liver disease, diabetes, pain, and inflammation. | 2015-01-29 |
20150031690 | FLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZINES - The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. | 2015-01-29 |
20150031691 | INHIBITORS OF BETA-SECRETASE - The present invention relates to compounds represented by Structural Formula (I): | 2015-01-29 |
20150031692 | SUBSTITUTED PYRANO AND FURANOQUINOLINES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to new substituted pyrano and furanoquinolines having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments. | 2015-01-29 |
20150031693 | PAK INHIBITORS FOR THE TREATMENT OF FRAGILE X SYNDROME - Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of Fragile X syndrome. | 2015-01-29 |
20150031694 | ANTIMICROBIAL AGENTS - The invention provides compounds of formula (I): wherein R | 2015-01-29 |
20150031695 | SMALL MOLECULE COMPOUNDS FOR TARGETING INFLAMMATORY CONDITIONS - Small molecule compounds for the treatment of inflammatory conditions, and pharmaceutical compositions and methods relating thereto. The compositions may be used for the treatment of conditions such as multiple sclerosis, type 2 diabetes, psoriasis, rheumatoid arthritis, Hashimoto's thyroiditis, and Crohn's disease. In some embodiments, the pharmaceutical composition and methods pertain to small molecule compounds previously known for the treatment of another condition, such as non-small-cell lung cancer (NSCLC). | 2015-01-29 |
20150031696 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF - The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure: | 2015-01-29 |
20150031697 | METHOD FOR PREVENTING ULTRAVIOLET RADIATION-INDUCED CUTANEOUS DAMAGE AND DEVELOPMENT OF SQUAMOUS CELL CARCINOMAS - Provided herein are methods of preventing skin cancer, where the methods comprise the step of administering an effective amount of at least one Hsp90 inhibitor to a subject at the risk of developing skin cancer, whereby the skin cancer is prevented in the subject. | 2015-01-29 |
20150031698 | s-TRIAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME - Novel s-triazine compounds are disclosed that have a formula represented by the following: | 2015-01-29 |
20150031699 | TREATMENT OF MYELODYSPLASTIC SYNDROME - The present invention relates to the use of Volasertib or a pharmaceutically acceptable salt thereof or the hydrate thereof for treating myelodysplastic syndrome (MDS). | 2015-01-29 |
20150031700 | Methods of Treating Cutaneous Flushing Using Selective Alpha-2-adrenergic Receptor Agonists - The present invention relates to a method of treating, reducing, inhibiting, preventing and/or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing reaction (e.g.: alcohol, chocolate, spices) by topical dermatological application of an effective dose of a composition comprising at least one α | 2015-01-29 |
20150031701 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS - Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia. | 2015-01-29 |
20150031702 | PI3K INHIBITORS FOR TREATING COUGH - The present invention is directed to compounds or pharmaceutically acceptable salts thereof for use in the treatment of cough, in particular idiopathic chronic cough, cough variant asthma, cough associated with thoracic tumour or lung cancer, viral and post-viral cough, upper airways cough syndrome (UACS) or post nasal drip cough, and cough associated with disorders such as gastro oesophageal reflux disease (both acid and non acid reflux), chronic bronchitis, chronic obstructive pulmonary disease (COPD), interstitial lung disease (such as idiopathic pulmonary fibrosis (IPF)), congestive heart disease, sarcoidosis and infection (such as whooping cough. | 2015-01-29 |
20150031703 | NOVEL FGFR3 FUSION - [Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. | 2015-01-29 |
20150031704 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE - The invention features a method of treating a peripheral vascular disease or a condition associated with a peripheral vascular disease by administering to a subject an effective amount of at least one phosphodiesterase type 5 inhibitor and at least one nitric oxide donor. The invention also features compositions formulated for topical or oral administration including at least one phosphodiesterase type 5 inhibitor, at least one nitric oxide donor, and a pharmaceutically acceptable carrier, as well as kits including these compositions. These methods, compositions, and kits can optionally include other therapeutic agents. | 2015-01-29 |
20150031705 | OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS - Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof. The active agents include, for example, alpha 1 antagonists, such as alpha 1a selective antagonists. | 2015-01-29 |
20150031706 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6. | 2015-01-29 |
20150031707 | METHOD FOR PREPARING NANO PARTICLES - The present invention relates to a method for manufacturing nano-scale particles of an active material. More particularly, the present invention relates to a method which uniformly mixes a surfactant having an HLB value of 8 or more and a melting point or glass transition temperature of 80° C. or lower and an active material, and mills the mixture using a roller mill, to thereby prepare nanoparticle powder from the active material. | 2015-01-29 |
20150031708 | MODULATORS OF CFTR - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention. | 2015-01-29 |
20150031709 | Heteroaryl Compounds and Methods of Use Thereof - Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia. | 2015-01-29 |
20150031710 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2015-01-29 |
20150031711 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2015-01-29 |
20150031712 | Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same - A treatment pack comprising: (a) multiple doses of a composition containing dipyridamole as an active ingredient; (b) packaging material; and (c) instructions for topical administration of said composition to the anterior segment of the eye to treat an anterior segment eye disorder. | 2015-01-29 |
20150031713 | ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to benzoquinazilinone compounds of formula (I) | 2015-01-29 |
20150031714 | METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION - Embodiments of the invention include methods of preventing and/or reducing the risk or severity of an allergic reaction in an individual. In some embodiments, particular small molecules are employed for prevention and/or reduction in the risk or severity of anaphylaxis. In at least particular cases, the small molecules are inhibitors of STAT3. In some cases, the small molecule comprises N-(1′,2-dihydroxy-1,2′-binaphthalen-4′-yl)-4-methoxybenzenesulfonamide. | 2015-01-29 |
20150031715 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 - The invention relates to compounds of formula I: wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to VLA-4 integrin antagonists to target cells expressing VLA-4. | 2015-01-29 |
20150031716 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS - The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 2015-01-29 |
20150031717 | Derivatives Of Protoberberine Biological Alkaloids And Use Of Same Inhibiting Ulcerative Colitis - Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically acceptable salts thereof show activity inhibiting ulcerative colitis and can be used in the preparation of drugs for same. | 2015-01-29 |
20150031719 | Topical Therapy for the Treatment of Migraines, Muscle Sprains, Muscle Spasms, Spasticity and Related Conditions - The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof. | 2015-01-29 |
20150031720 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2015-01-29 |
20150031721 | POLYMORPHIC FORMS OF COMPOUNDS AS PROLYL HYDROXYLASE INHIBITOR, AND USES THEREOF - The present invention relates to the polymorphic forms of the compound of Formula (I), preparation thereof including the preparation of intermediates and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the treatment of a disease, a disorder or a condition. | 2015-01-29 |
20150031722 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2015-01-29 |
20150031723 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases - A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon, uterus, nervous system, testis, adrenal gland, artery, vein, biliary tract, or eye. | 2015-01-29 |
20150031724 | AQUEOUS LIQUID PREPARATIONS AND LIGHT-STABILIZED AQUEOUS LIQUID PREPARATIONS - An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided. | 2015-01-29 |
20150031725 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided herein, inter alia, are compositions and methods useful for treating hyperproliferative diseases, including cancer and non-malignant hyperproliferative diseases. | 2015-01-29 |
20150031726 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds - Substituted phenylcarbamoyl alkylamino arenes; substituted phenylthiocarbamyl alkylamino arenes; substituted phenylcarbamoyl alkylamino heteroarenes; substituted phenylthiocarbamyl alkylamino heteroarenes; N-substituted aryl, N′-substituted aryl urea compounds; N-substituted aryl, N′-substituted heteroaryl urea compounds; N-substituted aryl, N′-substituted aryl thiourea compounds and N-substituted aryl, N′-substituted heteroaryl thiourea compounds are provided and may find use as androgen receptor modulators. The compounds may find particular use in treating prostate cancer, including castration-resistant prostate cancer and/or hormone-sensitive prostate cancer. | 2015-01-29 |
20150031727 | AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE - [Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. | 2015-01-29 |
20150031728 | Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures - Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent. | 2015-01-29 |
20150031729 | LOW-TACK SURFACE ANTI-MICROBIAL COATING COMPOSITION AND METHOD OF APPLICATION - A method for trapping and neutralizing or killing microorganisms on a surface includes: applying a low tack coating composition that comprises an antimicrobial agent onto an inanimate surface; in the coating, killing or neutralizing microorganisms encountered on the surface and encountered from the environment after the applying step is performed; forming a coating layer on the inanimate surface. The composition comprises a humectant and an antimicrobial, the antimicrobial including a monoquaternary ammonium compound or pharmaceutically acceptable salt thereof. The coating layer has antimicrobial cidal or static activity for at least about one hour. A low-tack antimicrobial composition is also included. | 2015-01-29 |
20150031730 | FUNGICIDAL 3-[(1,3-THIAZOL-4-YLMETHOXYIMINO)(PHENYL)METHYL]-2-SUBSTITUTED-- 1,2,4-OXADIAZOL-5(2H)-ONE DERIVATIVES - The present invention relates to 3-[(1,3-thiazol-4-ylmethoxyimino)(phenyl)methyl]-2-substituted-1,2,4-oxadiazol-5(2H)-one derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | 2015-01-29 |
20150031731 | POLYMORPH OF A PHARMACEUTICAL - A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed. | 2015-01-29 |
20150031732 | FEBUXOSTAT SOLID DISPERSION - The present invention provides a solid dispersion of febuxostat, processes for its preparation, pharmaceutical compositions comprising it and its use for the chronic management of hyperuricemia in patients with gout. | 2015-01-29 |
20150031733 | TETRAZOLINONE COMPOUNDS AND ITS USE - The present invention provides a compound having an excellent efficacy for controlling pests. A tetrazolinone compound of a formula (1): [wherein, R1 represents an C6-C16 aryl group, an C1-C12 alkyl group, a C3-C12 cycloalkyl group or an adamantyl group, etc., which each optionally be substituted; R2 represents a hydrogen atom, an C1-C12 alkyl group, or a halogen atom, etc.; R4 and R5 represent independently of each other a hydrogen atom or an C1-C3 alkyl group, etc.; R6, R7, R8 and R9 represent independently of each other a hydrogen atom, a halogen atom, an C1-C12 alkyl group, a C1-C12 haloalkyl group, an C2-C12 alkenyl group, a C3-C12 cycloalkyl group, an C1-C12 alkoxy group or a C1-C12 haloalkoxy group, etc.; X and Y represent independently of each other a sulfur atom or an oxygen atom; Q represents an oxygen atom or a sulfur atom; and R10 represents an C1-C6 alkyl group, etc.] shows an excellent controlling efficacy on pests. | 2015-01-29 |
20150031734 | PHARMACEUTICAL COMPOSITION CONTAINING MIRABEGRON - Provided is a mirabegron-containing pharmaceutical composition in which the leakage of mirabegron can be inhibited when the pharmaceutical composition is dispersed in a liquid, and in which the change in pharmacokinetics caused by the presence or absence of food intake is decreased. The pharmaceutical composition comprises an acid addition salt of alkyl sulfuric acid and mirabegron, and a base for modified release. | 2015-01-29 |
20150031735 | SOLID FORMS OF A TRANSTHYRETIN DISSOCIATION INHIBITOR - The present invention relates to solid forms of the N-methyl-D-glucamine (meglumine) salt of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions. | 2015-01-29 |
20150031736 | USE OF A PYRAZOLE DERIVATIVE IN THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Treatment may involve a single dose of the active ingredient by oral administration. | 2015-01-29 |
20150031737 | STABILIZED CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION COMPRISING GLICLAZIDE - The present invention provides a stabilized controlled-release pharmaceutical composition comprising gliclazide and sodium citrate as stabilizing agent; and process for the preparation of said pharmaceutical composition. | 2015-01-29 |
20150031738 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME - The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a | 2015-01-29 |
20150031739 | PANOBINOSTAT FOR USE IN THE TREATMENT OF HIV-1 - The present invention relates to uses and methods involving Panobinostat and HIV-1. In particular relates the present invention to Panobinostat for use in the treatment of HIV-1 and especially latent HIV-1. This is done using a low dosage of Panobinostat which is highly effective in depleting the HIV-1 reservoir. | 2015-01-29 |
20150031740 | COSMETIC COMPOSITION FOR STIMULATING THE CELLULAR ANTI-AGING FUNCTIONS OF THE SKIN - The use of a compound of general formula (I), where: R | 2015-01-29 |
20150031741 | COMPOSITIONS AND METHODS FOR IMPROVING LACTATION - The present disclosure relates to the use of pharmaceutical agents to manipulate serotonin in animal mammary glands. Use of the serotonin agents results in increased PTHrP levels, resulting in the release of calcium from the bone, which improves lactation. | 2015-01-29 |
20150031742 | TREATMENT OF UTERINE LEIOMYOMATA - Embodiments herein provide a therapy for uterine leiomyomata (UL) in women using a fatty acid synthase (FAS) inhibitor. Additionally, an analysis method for evaluating the likelihood of women developing UL during their lifetime is provided. | 2015-01-29 |
20150031743 | CELL TRANSFECTING FORMULATIONS OF SMALL INTERFERING RNA, RELATED COMPOSITIONS AND METHODS OF MAKING AND USE - Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions. | 2015-01-29 |
20150031744 | METHOD FOR PREDICTING AND DETECTING TUMOR METASTASIS - The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the prognosis of cancer in the subject. The invention further provides a method of diagnosing cancer, methods of treatment, kits for detecting mRNA expression of a CPE-ΔN, and inhibitors of CPE-ΔN and compositions thereof. | 2015-01-29 |
20150031745 | NANOCONJUGATES ABLE TO CROSS THE BLOOD-BRAIN BARRIER - The present disclosure is directed to nanoconjugates that cross the blood-brain barrier and methods of their therapeutic use. | 2015-01-29 |
20150031746 | METHODS AND COMPOSITIONS FOR NEUROPROTECTION - Disclosed herein are methods and kits useful for providing neuroprotection to neurons in the inner ear and to methods of treating inner ear diseases and disorders, including tinnitus and Mnire's disease. | 2015-01-29 |
20150031747 | METHODS AND COMPOSITIONS FOR MODULATING FACTOR VII EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing Factor VII and treating, preventing, or slowing progression of thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof. | 2015-01-29 |
20150031748 | MODULATING THE INTERACTION BETWEEN ZO-2/TJP2 AND A SNAIL ZINC FINGER TRANSCRIPTION FACTOR FAMILY MEMBER - There is provided a method of identifying candidate agents capable of modulating interaction between a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof. | 2015-01-29 |
20150031749 | BIOMARKER, USES THEREOF AND THERAPY - A method of determining the Crohn's disease status of a subject comprising the steps of determining the level of miR-29 in a sample from said subject; and comparing the level of miR-29 determined in step (a) with one or more reference values. | 2015-01-29 |
20150031750 | TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF. | 2015-01-29 |
20150031751 | COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN CANCER - The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described. | 2015-01-29 |
20150031752 | COATED LIPID COMPLEXES AND THEIR USE - The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions. | 2015-01-29 |
20150031753 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES - The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula: | 2015-01-29 |
20150031754 | APTAMER MODULATORS OF ESTROGEN RECEPTORS - The present invention relates to a nucleic acid aptamer molecule that includes a domain that binds to an estrogen receptor, molecular complexes that include the nucleic acid aptamer molecule and an estrogen receptor, and constructed DMA molecules and expression systems, as well as host cells, that the contain an RNA aptamer molecule of the invention. Use of these aptamers and encoding constructs to inhibiting estrogen receptor activity in a cell and to treat estrogen receptor-positive cancers is also described. | 2015-01-29 |
20150031755 | Nucleic Acids Specifically Binding CGRP - The present invention is related to a nucleic acid molecule capable of binding to CGRP, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′ HWn | 2015-01-29 |
20150031756 | LENTIVIRAL VECTORS AND USES THEREOF - The invention relates to compositions containing polynucleotide vectors capable of expressing a nucleic acid encoding a fusion polypeptide on the surface of a viral particle and/or a eukaryotic cell. | 2015-01-29 |
20150031757 | TREATING GLAUCOMA, CARDIOVASCULAR DISEASES, AND RENAL DISEASES - This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided. | 2015-01-29 |
20150031758 | TRANSITION METAL COMPLEXES OF A BIS[THIOHYDRAZIDE AMIDE] COMPOUND - The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof. | 2015-01-29 |
20150031759 | Analogues of (-)Picropodophyllin, Synthesis And Uses Thereof - Compounds, compositions, methods of making, and methods of using analogues of (−)-picropodophyllin, as well as a transgenic animal model and its use for identifying anticancer agents. | 2015-01-29 |
20150031760 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NERVOUS SYSTEM DISORDERS COMPRISING SULFURETIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical composition for preventing or treating nervous system disorders, which contains sulfuretin or a pharmaceutically acceptable salt thereof, and a method of using the composition to prevent or treat nervous system disorders. Moreover, the present invention relates to a functional food composition for alleviating nervous system disorders, which contains sulfuretin or a pharmaceutically acceptable salt thereof. The pharmaceutical composition and the functional food composition can be effectively used to prevent or treat degenerative brain disorders caused by a variety of cerebral nervous system abnormalities in persons, as well as depressive disorder and anxiety. | 2015-01-29 |
20150031761 | USE OF 5-AMINOLEVULINIC ACID AND DERIVATIVES IN A SOLID FORM FOR PHOTODYNAMIC TREATMENT AND DIAGNOSIS - The present invention relates to the use of a photosensitiser which is 5-ALA or a precursor or derivative thereof (e.g. an ALA ester), in the manufacture of a pharmaceutical product for use in the photodynamic treatment or diagnosis of cancer, an infection associated with cancer, or in the treatment or diagnosis of a non-cancerous condition, wherein said pharmaceutical product is in the form of a solid. The invention also relates to solid pharmaceutical products for use in such methods, e.g. suppositories, pessaries, tablets, pellets and capsules which comprise 5-ALA or a precursor or derivative thereof (e.g. an ALA ester) and at least one pharmaceutically acceptable carrier or excipient. Such products are particularly suitable for use in the photodynamic treatment or diagnosis of cancerous or non-cancerous conditions in the lower part of the gastrointestinal system or in the female reproductive system, e.g. in the treatment or diagnosis of colorectal cancer or cervical cancer. | 2015-01-29 |
20150031762 | Antimicrobial Formulations with Pelargonic Acid - An antimicrobial composition for extending the shelf-life of water, feed or feed ingredients, comprising: water, a mixture of CrC18 organic acids, a mixture of CrC24 aldehydes, 5-25 wt. % pelargonic acid, and 5-30 wt. % trans-2-hexenal. | 2015-01-29 |
20150031763 | DEODORIZATION OF PERACIDS - The present invention relates to compositions of peracids, such as peroxycarboxylic acids, having reduced odor compared to conventional peracid compositions. The invention further relates to methods employing such compositions, and methods of making these compositions. Typically, the reduced-odor antimicrobial compositions include an alcohol for the esterification reaction to remove short- to mid-chain length malodorous carboxylic acids. | 2015-01-29 |
20150031764 | SUGAR ESTER PERACID ON SITE GENERATOR AND FORMULATOR - Methods and systems for on-site generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed. | 2015-01-29 |
20150031765 | TREATMENT OF COGNITIVE IMPAIRMENT - The present invention relates to a compound with the core structure of formula (I), or pharmaceutically acceptable salts or esters, solvates, or prodrugs thereof, for use in the treatment of cognitive impairment in a mammal. The compound is preferably isosteviol or steviol, or pharmaceutically acceptable salts or esters, solvates, or prodrugs thereof. | 2015-01-29 |
20150031766 | SURFACTANT PEROXYCARBOXYLIC ACID COMPOSITIONS - The present invention relates to compositions including surfactant peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism. | 2015-01-29 |
20150031767 | FULVIC ACID AND ANTIBIOTIC COMBINATION FOR THE INHIBITION OR TREATMENT OF MULTI-DRUG RESISTANT BACTERIA - Fulvic acid as the active ingredient is used in the treatment or inhibition of multi-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended-spectrum lactamase (ESBL) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, | 2015-01-29 |
20150031768 | C-HALOGEN BOND FORMATION - Methods of halogenating a carbon containing compound having an sp3 C—H bond are provided. Methods of fluorinating a carbon containing compound comprising halogenation with Cl or Br followed by nucleophilic substitution with F are provided. Methods of direct oxidative C—H fluorination of a carbon containing compound having an sp3 C—H bond are provided. The halogenated products of the methods are provided. | 2015-01-29 |
20150031769 | METHODS FOR REDUCING TRIGLYCERIDE, TOTAL CHOLESTEROL AND LOW DENSITY LIPOPROTEIN BLOOD LEVELS - A compound of Formula (I): | 2015-01-29 |
20150031770 | Pharmaceutical Formulations of HDAC Inhibitors - This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxyl-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc. | 2015-01-29 |
20150031771 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATIC FIBROSIS AND CIRRHOSIS CONTAINING RAMALIN - There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived from | 2015-01-29 |
20150031772 | ADJUSTABLE BIOACTIVE AGENT DISPERSION WITHIN A POLYMERIC COATING - A coating comprised of a polymeric material and a bioactive agent where the properties of the casting solvent dictate the dispersion of the embedding bioactive agent. In preferred embodiments, controlled release of the bioactive agent is achieved by homogeneous dispersion of the bioactive agent within the coating. A further aspect of the invention is directed to formulations where the heterogeneous dispersion of the bioactive agent provides an initial rapid release of the bioactive agent. Methodology for production of coating formulations of the desired properties and the application of the coating to an article are also described. | 2015-01-29 |
20150031773 | Pharmaceutical Composition for Preventing or Treating Muscle Wasting-Related Disease Comprising Diaminodiphenylsulfone or Pharmaceutically Acceptable Salt Thereof - The present invention relates to a pharmaceutical composition for preventing or treating a muscle wasting-related disease comprising diaminodiphenylsulfone (Dapsone; DDS) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition according to the present invention may be effectively used to prevent or treat a muscle wasting-related disease by increasing muscle mass, preventing muscle loss and effectively restoring muscle function. | 2015-01-29 |